ABK Biomedical Gains IDE Approval for Pivotal Study of Eye90 Microspheres to Treat Hepatocellular Carcinoma
May 30, 2023—ABK Biomedical, Inc. announced it has received Investigational Device Exemption approval from the FDA to commence a multicenter pivotal clinical study in the United States for the company’s imageable Eye90 microspheres yttrium-90 (Y90) radioembolization therapy.
